CAR T-Cell Therapy for Mantle Cell Lymphoma: Tycel Jovelle Phillips, MD

Video

The clinical associate professor from the Rogel Cancer Center at Michigan Medicine discussed the future of CAR T-cell therapy in mantle cell lymphoma patients.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Tycel Jovelle Phillips, MD, clinical associate professor, Division of Hematology and Oncology, Department of Internal Medicine, Rogel Cancer Center, Michigan Medicine, about the future of CAR T-cell therapy in mantle cell lymphoma (MCL) patients.

Phillips discussed how CAR T-cell therapy appears to be agnostic to some of the high-risk features that distinguish frontline treatment outcomes in patients with MCL. As such, this modality may have clinical utility as up-front treatment to improve outcomes in patients with high-risk disease, Phillips explains. However, developing improved toxicity management, particularly with regard to CAR T-cell therapy–related neurotoxicity, is important in MCL, Phillips adds.

Increased exposure to using CAR T-cell therapy will increase provider comfortability with the modality and improve toxicity-management strategies, Phillips continues. With additional data emerging, FDA approvals of novel CAR T-cell therapies in MCL could be on the horizon to provide more options to patients, Phillips concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.